Verzenio(r) Significantly Reduced the Risk of Cancer Recurrence by 25% for People with HR+, HER2- High Risk Early Breast Cancer

Source :: Plus Company Updates. September 22, 2020
Publication Year :: 2020
Abstract: United States: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced Verzenio(r) (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) [...]

Subjects :: Eli Lilly and Co.
Cancer recurrence -- Risk factors
Cancer prevention
Pharmaceutical industry
Abemaciclib
Breast cancer -- Risk factors
Adjuvant chemotherapy
General interest
News, opinion and commentary
Verzenio (Medication)

Tools